Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 9;13(1):29.
doi: 10.1186/s12348-023-00350-5.

Risk of failing both methotrexate and mycophenolate mofetil from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial

Amit K Reddy  1   2 , D Claire Miller  1 , Amol A Sura  1   2 , S R Rathinam  3 , John A Gonzales  1   2 , Radhika Thundikandy  3 , Anuradha Kanakath  4 , Bala Murugan  5 , Rajesh Vedhanayaki  3 , Lyndell L Lim  6 , Eric B Suhler  7 , Thuy Doan  1   2 , Hassan A Al-Dhibi  8 , Debra A Goldstein  9 , Lourdes Arellanes-Garcia  10 , Nisha R Acharya  11   12   13
Affiliations

Risk of failing both methotrexate and mycophenolate mofetil from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial

Amit K Reddy et al. J Ophthalmic Inflamm Infect. .

Abstract

Background: The antimetabolites methotrexate (MTX) and mycophenolate mofetil (MMF) are commonly used as initial corticosteroid-sparing treatment for uveitis. There is little data examining risk factors for failing both MTX and MMF. The objective of this study is to determine risk factors for failing both MTX and MMF in patients with non-infectious uveitis.

Main body: This is a sub-analysis of the First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial, which was an international, multicenter, block-randomized, observer-masked, comparative effectiveness trial comparing MTX and MMF as initial treatments for non-infectious uveitis. This study was undertaken at multiple referral centers in India, the United States, Australia, Saudi Arabia and Mexico between 2013 and 2017. A total of 137 patients who completed all 12 months of follow-up from the FAST trial, were included in this study. The primary outcome was failing both antimetabolites over the 12 months of the trial. Potential predictors included: age, sex, bilateral involvement, anatomic location of the uveitis, presence of cystoid macular edema (CME) and retinal vasculitis at baseline visit, uveitis duration, and country/study sites as risk factors for failing both MTX and MMF. The presence of retinal vasculitis posterior to the equator on fluorescein angiogram was associated with failing both MTX and MMF.

Conclusion: Retinal vasculitis may be a risk factor for failing multiple antimetabolites. Clinicians could consider more quickly advancing these patients to other medication classes, such as biologics.

Keywords: Immunomodulatory therapy; Methotrexate; Mycophenolate mofetil; Non-infectious uveitis; Retinal vasculitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492–513. doi: 10.1016/s0002-9394(00)00659-0. - DOI - PubMed
    1. Gangaputra S, Newcomb CW, Liesegang TL, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116(11):2188–98 e1. doi: 10.1016/j.ophtha.2009.04.020. - DOI - PMC - PubMed
    1. Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149(3):423–32 e1-2. doi: 10.1016/j.ajo.2009.09.026. - DOI - PMC - PubMed
    1. Durrani K, Zakka FR, Ahmed M, Memon M, Siddique SS, Foster CS. Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease. Surv Ophthalmol. Nov-Dec. 2011;56(6):474–510. doi: 10.1016/j.survophthal.2011.05.003. - DOI - PubMed
    1. Suhler EB, Jaffe GJ, Fortin E, et al. Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. Ophthalmology. 2020; 10.1016/j.ophtha.2020.10.036 - PubMed